2029, CRM and Pharma - Pharma Rep Focus

Boehringer Ingelheim agrees $2bn siRNA therapeutic collaboration

European Pharmaceutical Review

JANUARY 3, 2024

Boehringer Ingelheim’s recent M&A activity In November 2023, Boehringer announced that it planned to acquire the Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF). Under the new agreement, Ribo will receive an upfront payment and is also eligible for success-based milestones and tiered royalties.

CRM

CRM Pharma Pharmaceutical Management

Making Sense of the Latest Changes to the Market Access Landscape

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing

Marketing Pharma Manufacturing Healthcare

Pharma Rep Focus

Boehringer Ingelheim agrees $2bn siRNA therapeutic collaboration

Making Sense of the Latest Changes to the Market Access Landscape

Webinars

Stay Connected